Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L.

J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x.

2.

More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.

Santagostino E.

Haemophilia. 2013 Jan;19 Suppl 1:8-11. doi: 10.1111/hae.12050. Review.

PMID:
23278994
3.

Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.

Kurth MA, Dimichele D, Sexauer C, Sanders JM, Torres M, Zappa SC, Ragni M, Leonard N.

Haemophilia. 2008 Jan;14(1):50-5. Epub 2007 Oct 18. Erratum in: Haemophilia. 2008 Jul;14(4):878. Haemophilia. 2008 Mar;14(2):414.

PMID:
17941829
4.

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.

Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E.

Haemophilia. 2014 Jan;20(1):83-91. doi: 10.1111/hae.12263. Epub 2013 Nov 19.

5.
6.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.

Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee.

Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.

PMID:
26202305
7.

Immune tolerance induction in patients with hemophilia A.

Astermark J.

Thromb Res. 2011 Jan;127 Suppl 1:S6-9. doi: 10.1016/j.thromres.2010.10.006. Epub 2010 Nov 5.

PMID:
21056905
8.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
9.
10.
11.

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.

Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group.

Haemophilia. 2007 Jul;13(4):373-9.

PMID:
17610550
12.

The role of VWF for the success of immune tolerance induction.

Kreuz W.

Thromb Res. 2008;122 Suppl 2:S7-S12. doi: 10.1016/S0049-3848(08)70003-3. Review.

PMID:
18549910
13.

ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Oldenburg J, Austin SK, Kessler CM.

Haemophilia. 2014 Sep;20 Suppl 6:17-26. doi: 10.1111/hae.12466. Review.

PMID:
24975701
14.

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

Ettingshausen CE, Kreuz W.

Haemophilia. 2013 Jan;19 Suppl 1:12-7. doi: 10.1111/hae.12051. Review.

PMID:
23278995
15.

VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.

Gringeri A.

Haemophilia. 2007 Dec;13 Suppl 5:73-7. doi: 10.1111/j.1365-2516.2007.01579.x.

PMID:
18078402
16.

Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.

Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.

Haemophilia. 2012 May;18(3):469-75. doi: 10.1111/j.1365-2516.2011.02655.x. Epub 2011 Sep 22.

PMID:
21943193
17.

Role of von Willebrand factor in immune tolerance induction.

Ettingshausen CE, Kreuz W.

Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S27-31. Review.

PMID:
15849524
18.

A review of immune tolerance induction with Haemate P in haemophilia A.

Escuriola Ettingshausen C, Kreuz W.

Haemophilia. 2014 May;20(3):333-9. doi: 10.1111/hae.12288. Epub 2013 Oct 24. Review.

19.

Epidemiology of inhibitors and current treatment strategies.

Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group.

Haematologica. 2003 Jun;88(6):EREP04. Review.

PMID:
12826530
20.

Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.

Mathieu S, Crampe C, Dargaud Y, Lavigne-Lissalde G, Escuriola-Ettingshausen C, Tardy B, Meley R, Thouvenin S, Stephan JL, Berger C.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):940-5. doi: 10.1097/MBC.0000000000000300.

PMID:
26517064

Supplemental Content

Support Center